A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US

References

• WallaceDVDykewiczMSBernsteinDIThe diagnosis and management of rhinitis: an updated practice parameterJ Allergy Clin Immunol20081222 SupplS1S8418662584
   PubMed Web of Science ®Google Scholar
• NathanRAMeltzerEODereberyJThe prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America surveyAllergy Asthma Proc200829660060819173786
   PubMed Web of Science ®Google Scholar
• DalalAAStanfordRHenryHBorahBEconomic burden of rhinitis in managed care: a retrospective claims data analysisAnn Allergy Asthma Immunol20081011232918681080
   PubMed Web of Science ®Google Scholar
• LevetinEVan de WaterPChanging pollen types/concentrations/distribution in the United States: fact or fiction?Curr Allergy Asthma Rep20088541842418682110
   PubMed Web of Science ®Google Scholar
• WaynePFosterSConnollyJBazzazFEpsteinPProduction of allergenic pollen by ragweed (Ambrosia artemisiifolia L.) is increased in CO2-enriched atmospheresAnn Allergy Asthma Immunol200288327928211926621
   PubMed Web of Science ®Google Scholar
• ZhangYBieloryLZhongyuanMTingCRobockAGeorgopoulosPAllergenic pollen season variations in the past two decades under changing climate conditions in the United StatesGlob Chang Biol20142141581158925266307
   PubMed Web of Science ®Google Scholar
• BieloryLLyonsKGoldbergRClimate change and allergic diseaseCurr Allergy Asthma Rep201212648549423065327
   PubMed Web of Science ®Google Scholar
• MeltzerEOGrossGNKatialRStormsWWAllergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing LimitationsJ Fam Pract2012612 SupplS5S1022312622
   PubMedGoogle Scholar
• GrossGKatialRHadleyJMarpleBRyanSStoloffSNasal Allergy Survey Assessing Limitations (NASL) 2010 Survey: allergic rhinitis continues to impact patient quality of lifeJ Allergy Clin Immunol2011127Issue 2AB217
   Web of Science ®Google Scholar
• CarrWBernsteinJLiebermanPA novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitisJ Allergy Clin Immunol201212951282128922418065
   PubMed Web of Science ®Google Scholar
• MeltzerEOLaForceCRatnerPPriceDGinsbergDCarrWMP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safetyAllergy Asthma Proc201233432433222856633
   PubMed Web of Science ®Google Scholar
• HampelFCRatnerPVan BavelJDouble-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery deviceAnn Allergy Asthma Immunol2010105216817320674829
   PubMed Web of Science ®Google Scholar
• MeltzerERatnerPBachertCClinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysisInt Arch Allergy Immunol2013161436937723652808
   PubMed Web of Science ®Google Scholar
• FDA Guideline [webpage on the Internet]Guidance for Industry Allergic Rhinitis: Clinical Development Programs for Drug ProgramsUS Department of Health and Human Services, FDA Center for Drug Evaluation and Research2000 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071293.pdfAccessed May 9, 2016
   Google Scholar
• EMA GuidelineGuideline on the Clinical Development of Medicinal Products for the Treatment of Allergic Rhinoconjunctivitis CHMP/EWP/2455/022004 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003554.pdfAccessed May 9, 2016
   Google Scholar
• JuniperEFGuyattGHDevelopment and testing of a new measure of health status for clinical trials in rhinoconjunctivitisClin Exp Allergy199121177832021881
   PubMed Web of Science ®Google Scholar
• ZiskaLKnowltonKRogersCRecent warming by latitude associated with increased length of ragweed season in central North AmericaPNAS2011108104248425121368130
   PubMed Web of Science ®Google Scholar
• Van de WaterPKKeeverTMainCELevetinEAn assessment of predictive forecasting of Juniperus Ashei pollen movement in the southern great plains, USAInt J Biometerol20034827482
   Web of Science ®Google Scholar
• DaviesJMGrass pollen allergens globally: the contribution of subtropical grasses to burden of allergic respiratory diseasesClin Exp Allergy201444679080124684550
   PubMed Web of Science ®Google Scholar
• ArbesSJGergenPJEliotLZeldinDCPrevalences of positive skin test responses to 10 common allergens in the US population: results from the Third National Health and Nutrition Examination SurveyJ Allergy Clin Immunol2005116237738316083793
   PubMed Web of Science ®Google Scholar
• Allergy and Asthma Center of Austin [homepage] Available at: http://www.nosneezes.comAccessed May 9, 2016
   Google Scholar
• San Antonio Express-News [webpage on the Internet]Cedar and Allergy Symptoms Hit Highest Levels of the Season2014 http://www.mysanantonio.com/business/health-care/article/Cedar-and-allergy-symptoms-hit-highest-levels-of-5150578.phpAccessed September 25, 2014
   Google Scholar
• CzerwinskiEWMidoro-HoriutiTWhiteMABrooksEGGoldblumRMCrystal structure of Jun a 1, the major cedar pollen allergen from Juniperus ashei, reveals a parallel B-helical coreJ Biological Chem2005280537403746
   Web of Science ®Google Scholar
• BousquetPJDemolyPDevillierPMesbahKBousquetJImpact of allergic rhinitis on quality of life in primary careInt Arch Allergy Immunol2013160439340023183377
   PubMed Web of Science ®Google Scholar
• RidoloEMontagniMMelliVBonzanoLIncorvaiaCCanonicaGWA role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitisTher Deliv20156665365925913181
   PubMedGoogle Scholar
• PriceDShahSBhatiaSA new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitisJ Investig Allergol Clin Immunol2013237495503
   PubMed Web of Science ®Google Scholar
• KlimekLBachertCMosgesREffectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional studyAllergy Asthma Proc2015361404725562555
   PubMed Web of Science ®Google Scholar
• SalapatekAMLeeJPatelDSolubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitisAllergy Asthma Proc201132322122921477425
   PubMed Web of Science ®Google Scholar
• BousquetJBachertCBernsteinJAdvances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gapsExpert Opin Pharmacother201516611625387541
   PubMed Web of Science ®Google Scholar
• Dymista [package insert]Somerset, NJMeda Pharmaceuticals2012
   Google Scholar
• BergerWEShahSLiebermanPLong-term, randomized safety study of MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitisJ Allergy Clin Immunol Pract20142217918524607046
   PubMed Web of Science ®Google Scholar
• KlimekLBousquetJPriceDSafety evaluation of MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitisExp Opin Drug Safety2016151117129
   PubMed Web of Science ®Google Scholar